


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO. 09/391666 <b>RECEIVED</b> AUG 18 2000 TECH CENTER 1600/2900
	APPLICANT Andrew D. Murdin et al	
	FILING DATE September 7, 1999	GROUP 1643

## U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
guc	4,245,050		Nakanishi et al.	435	191	
	5,015,580		Christou et al.	800	267	
	5,151,264		Samain et al.	424	1,21	
guc	5,075,109		Tice et al.	424	193.1	

## FOREIGN PATENT DOCUMENTS


	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
guc	WO 98/02546		WIPO			YES	NO
	WO 93/24640		WIPO				
	WO 94/27435		WIPO				
	WO 91/06282		WIPO				
	WO 95/34308		WIPO				
guc	WO 94/24263		WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

guc	1	Grayston et al. (1995), Journal of Infectious Diseases 168:1231-1235					
	2	Campos et al. (1995), Investigation of Ophthalmology and Visual Science 36:1477-1491					
	3	Grayston et al (1990), Journal of Infectious Diseases 161:618-625					
	4	Marrie (1993), Clinical Infectious Diseases. 18:501-515					
	5	Wang et al (1986), Chlamydial infections. Cambridge University Press, Cambridge. p. 329-333					
guc	6	Normann et al (1998), Acta Paediatrica, 87:23-27					
EXAMINER:		Shin-Lin Chen		DATE CONSIDERED:		6-1-94	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO. 09/391,606
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Andrew D. Murdin et al	
		FILING DATE September 7, 1999	GROUP 1643



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
7	Saikku et al. (1988), Lancet 983-985	
8	Thom et al. (1992), JAMA 268:68-72	
9	Linnanmaki et al. (1993), Circulation 87:1130-1134	
10	Saikku et al. (1992), Annals Internal Medicine 116:273-278	
11	Melnick et al (1993), American Journal of Medicine 95:499-504	
12	Shor et al. (1992), South African. Medical Journal 82:158-161	
13	Kuo et al. (1993), Journal of Infectious Diseases 167:841-849	
14	Kuo et al. (1993), Arteriosclerosis and Thrombosis 13:1501-1504	
15	Campbell et al (1995), Journal of Infectious Diseases 172:585-588	
16	Chiu et al. Circulation, 1997, Oct.7; 96(7);2144-2148	
17	Ramirez et al (1996) Annals of Internal Medicine 125:979-982	
18	Jackson et al. Abst. K121, p272, 36th ICAAC, 15-18 Sept. 1996, New Orleans	
19	Fong et al (1997) Journal of Clinical Microbiology 35:48-52	
20	Hahn DL, et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1998 Jan; 80(1): 45-49.	
21	Hahn DL, et al. Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect. 1996 Dec; 117(3): 513-517.	
22	Bjornsson E, et al. Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69	
23	Hahn DL. Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351	
24	Allegra L, et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168	
25	Hahn DL, et al. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230	
EXAMINER: Shin-Lin Chen		DATE CONSIDERED: 6-1-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-971 MIS:bh	SERIAL NO. 09/391,606
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Andrew D. Murdin et al	
		FILING DATE September 7, 1999	GROUP 1643



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

62	26	Pal et al. (1996) Infection and Immunity. 64:5341
	27	Jones et al. (1995) Vaccine 13:715-723
	28	Igietsemes et al. (1993) Immunology 5:317 (Duplicate See #29 below)
	29	Igietseme et al (1993) Regional Immunology 5:317-324
	30	Magee et al (1993) Regional Immunology 5: 305-311
	31	Landers et al (1991) Infection & Immunity 59:3774-3777
	32	Magee et al (1995) Infection & Immunity 63:516-521
	33	Cotter et al. (1995) Infection and Immunity 63:4704-4714
	34	Campbell et al (1990) Infection and Immunity 58:93-97
	35	McCafferty et al (1995) Infection and Immunity 63:2387-2389
**	36	Knudsen et al (1996) Third Meeting of the European Society for Chlamydia Research, Vienna
	37	Wiedmann-Al-Ahmad M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of Chlamydia pneumoniae. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704
	38	Xiang, 1995, Immunity 2: 129-35
	39	Tang et al, Nature 1992; 356:152-154
	40	Davis et al., Vaccine 1994, 12:1503-1509
	41	Yang et al, 1993, Infection & Immunity, vol. 61, pp 2037-40
62	42	Chi E.Y., Kuo C.C., Grayston J.T. 1987. Unique ultrastructure in the elementary body of Chlamydia sp strain TWAR. J. Bacteriol 169(8): 3757-63
EXAMINER:	Shin-Lin Chen	DATE CONSIDERED: 6-1-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.